GSK plc (GSK)

NYSE: GSK · Real-Time Price · USD
39.85
+0.33 (0.84%)
Sep 26, 2025, 4:00 PM EDT - Market closed
0.84%
Market Cap 80.21B
Revenue (ttm) 43.34B
Net Income (ttm) 4.69B
Shares Out 4.05B
EPS (ttm) 1.13
PE Ratio 17.10
Forward PE 8.53
Dividend $1.62 (4.06%)
Ex-Dividend Date Aug 15, 2025
Volume 4,760,826
Open 39.93
Previous Close 39.52
Day's Range 39.46 - 40.23
52-Week Range 31.72 - 42.63
Beta 0.29
Analysts Hold
Price Target n/a
Earnings Date Oct 29, 2025

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]

Sector Healthcare
Founded 1715
Employees 68,629
Stock Exchange NYSE
Ticker Symbol GSK
Full Company Profile

Financial Performance

In 2024, GSK's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.

Financial numbers in GBP Financial Statements

News

GSK plc (GSK) plc Presents at Bank of America Global Healthcare Conference 2025 Transcript

GSK plc (NYSE:GSK) plc Bank of America Global Healthcare Conference 2025 September 24, 2025 4:00 AM EDT Company Participants Julie Brown - CFO & Executive Director Tony Wood - Chief Scientific Office...

3 days ago - Seeking Alpha

Pi Health to Collaborate with GSK to Enhance Clinical Research Services

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pi Health, a global health technology and clinical research company, today announced it will provide fully outsourced clinical research services in a GSK clinical tr...

3 days ago - Business Wire

GSK to submit label update for Leucovorin at FDA's request, does not intend to market it for autism

CNBC's Angelica Peebles joins 'Fast Money' with breaking news on GSK and its drug Leucovorin.

5 days ago - CNBC Television

FDA approves drug that Trump due to suggest as autism treatment

The U.S. Food and Drug Administration announced approval of leucovorin, a form of folic acid that U.S. President Donald Trump was slated to suggest as a treatment for autism symptoms at a White House ...

5 days ago - Reuters

UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit

British pharmaceutical giant GSK committed to investing at least $30 billion in U.S. research and developing and manufacturing over the next five years.

10 days ago - CNBC

GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs

GSK and Eli Lilly are the latest to unveil plans to add to manufacturing and increase other operations in America.

Other symbols: LLY
11 days ago - WSJ

GSK plans $30 billion US investment as pharma tariff threat looms

GSK said on Wednesday it plans to invest $30 billion in research and development and supply chain infrastructure in the United States over the next five years, after U.S. President Donald Trump arrive...

11 days ago - Reuters

GSK Says It Will Spend $30B on U.S. Manufacturing and R&D

The U.K.-based firm and other drugmakers are seeking to avoid tariffs on drugs imported into the U.S.

11 days ago - Barrons

Dividend Income Summary: Lanny's July 2025 Summary

In July, we (my wife and I) received a dividend income total of $4,161.64. My other two Vanguard ETFs – S&P 500 (VOO) and Dividend Appreciation ETF (VIG) - both paid in July. We had a solid increase m...

Other symbols: BNLBNSCMCSCOIRMITWLEG
12 days ago - Seeking Alpha

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...

17 days ago - Reuters

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

Wave Life Sciences Ltd. WVE stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency.

Other symbols: WVE
24 days ago - Benzinga

Dynavax's shingles vaccine shows similar immune response to GSK's shot in study

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in early-to-mid-s...

Other symbols: DVAX
5 weeks ago - Reuters

GSK's antibiotic drug gepotidacin gets priority review by FDA

British drugmaker GSK said on Monday its supplemental new drug application for antibiotic drug gepotidacin has been accepted for priority review by the U.S. Food and Drug Administration for the oral t...

6 weeks ago - Reuters

GSK to Receive $370 Million in U.S. Patent Litigation Settlement

The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination mRNA vaccine products made by BioNTech and Pfizer.

7 weeks ago - WSJ

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

2 months ago - WSJ

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...

2 months ago - Forbes

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.

2 months ago - CNBC Television

Trump pressures 17 pharma CEOs to cut US drug prices

U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...

2 months ago - Reuters

Trump posts letters to 17 pharmaceutical companies about drug prices

CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.

2 months ago - CNBC Television

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...

2 months ago - CNBC

GSK plc (GSK) Q2 2025 Earnings Call Transcript

GSK plc (NYSE:GSK) Q2 2025 Earnings Conference Call July 30, 2025 7:00 AM ET Company Participants Deborah Jayne Waterhouse - CEO of ViiV Healthcare & President of Global Health Emma Natasha Walmsley ...

2 months ago - Seeking Alpha

GSK CEO: Innovation is the secret to bringing down cost of overall healthcare

Emma Walmsley, GSK CEO, joins CNBC's 'Squawk on the Street' to discuss the company's most recent earnings, innovation pipeline, the potential impact of tariffs on pharmaceuticals, and much more.

2 months ago - CNBC Television

GSK in talks with Trump administration on U.S. drug pricing, CEO says

British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, becoming the latest pharmaceutical company to acknowledge action under pressur...

2 months ago - Reuters

GSK expects annual sales and profit at top end of forecast range

British drugmaker GSK said on Wednesday it expects to report annual sales and profit towards the top end of its forecast range, adding that its outlook includes the impact of tariffs in place so far a...

2 months ago - Reuters

GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval

GSK's diversified portfolio and strong HIV/specialty medicines offer stability, but growth prospects remain modest amid stiff competition and legal overhangs. Despite a robust pipeline and management'...

2 months ago - Seeking Alpha